“Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google executive…

The four-year-old Isomorphic Labs was spun off from DeepMind in 2021 as a stand-alone subsidiary under Alphabet. In July, it announced deals to work on research with Eli Lilly & Co. and Novartis to leverage its AI technology — namely AlphaFold, its model that predicts a protein’s 3D structure — to discover therapeutics against multiple targets.

‘We’re looking at oncology, cardiovascular, neurodegeneration, all the big disease areas, and I think by the end of this year, we’ll have our first drug,’ Hassabis told The Financial Times on Tuesday.”

From Quartz.